RBC Capital Downgrades PTC Therapeutics (PTCT) to Sector Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- Wall Street ends down as US-Iran peace optimism fades
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
PTC Therapeutics (PTCT) Shares To See Upside, Even in Oppenheimer's Worst Case Scenario
February 25, 2016 7:48 AM ESTOppenheimer analyst, Christopher Marai, thinks the RTF is a setback for PTC Therapeutics (NASDAQ: PTCT) but it represents a delay rather than a stopping point. Revenue from Europe is likely to be uneffected and with the company trading near cash value, the shares represent a good risk reward. No change to Outperform rating but the PT goes to $111 from $135 as he removes the contribution... More
Jefferies Upgrades PTC Therapeutics (PTCT) to Hold
February 24, 2016 8:44 AM ESTJefferies upgraded PTC Therapeutics (NASDAQ: PTCT) from Underperform to Hold with a price target of $12.00 (from $18.00).
Analyst Gena Wang commented, "After FDA's Refuse to File letter, we see slim chance of approval for ataluren in DMD in US; however, EU decision remains unclear.... More
PTC Therapeutics (PTCT) Price Target Cut by 60% - Wedbush
February 24, 2016 8:41 AM ESTWedbush analyst, Heather Behanna, cut her price target on PTC Therapeutics (NASDAQ: PTCT) to $27 from $65 after Translarna stumbles in the US. No change to the Outperform rating.
Monday night, PTC received an RTF letter from FDA. The analyst said they do not yet know why the RTF was issued; they anticipate an update on its earnings call on February 29th with more... More
PTC Therapeutics (PTCT) Announces Receipt of FDA Refuse to File Letter for Translarna NDA
February 23, 2016 8:15 AM ESTPTC Therapeutics, Inc. (Nasdaq: PTCT) announced that it received yesterday evening a Refuse to File letter from the United States Food and Drug Administration (FDA) regarding PTC's New Drug Application (NDA) for Translarna (ataluren), an oral, first-in-class, protein restoration therapy for the treatment of nonsense... More
